North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-07-04-01 Anti-emetics
| Metoclopramide |
|
Formulary
|
|
 MHRA Drug Safety Update Alert (Aug 2013): Metoclopramide: risk of neurological adverse effects |
|
Links
- MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs
- MHRA Drug Safety Update (Dec 2007): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks
- MHRA Drug Safety Update (Jan 2015): Cox-2 selective inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): Cardiovascular safety.
- MHRA Drug Safety Update (June 2013): Diclofenac: new contraindications and warnings
- MHRA Drug Safety Update (June 2015): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk
- MHRA Drug Safety Update (Oct 2012): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks
- MHRA Drug Safety Update Alert (Aug 2013): Metoclopramide: risk of neurological adverse effects
NENC Palliative and End of Life Care Symptom Control Guidelines- NICE ES23: COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19
- NICE NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
- NICE NG41: Spinal injury: assessment and initial management
- NICE NG59: Low back pain and sciatica in over 16s: assessment and management
- NICE NG62: Cerebral palsy in under 25s: assessment and management
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV Safe Transfer of Prescribing Guidance